Human medicines European public assessment report (EPAR): Amyvid, florbetapir (18F), Date of authorisation: 14/01/2013, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Vydura, rimegepant, Date of authorisation: 25/04/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Instanyl, fentanyl, Date of authorisation: 20/07/2009, Revision: 42, Status: Authorised

Start of procedure: Extension of marketing authorisation (18 September 2026 - 15 October 2026)

CHMP PROM minutes for the meeting on 13 April 2026

Human medicines European public assessment report (EPAR): Kostaive, zapomeran, Date of authorisation: 12/02/2025, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Eklira Genuair, aclidinium bromide, Date of authorisation: 20/07/2012, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Duaklir Genuair, aclidinium bromide,formoterol, Date of authorisation: 19/11/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Byfavo, remimazolam, Date of authorisation: 26/03/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Date of authorisation: 27/11/1995, Revision: 53, Status: Authorised